NO20001171L - FremgangsmÕte ved økning av benvolum under anvendelse av ikke naturlig forekommende FP-selektive agonister - Google Patents

FremgangsmÕte ved økning av benvolum under anvendelse av ikke naturlig forekommende FP-selektive agonister

Info

Publication number
NO20001171L
NO20001171L NO20001171A NO20001171A NO20001171L NO 20001171 L NO20001171 L NO 20001171L NO 20001171 A NO20001171 A NO 20001171A NO 20001171 A NO20001171 A NO 20001171A NO 20001171 L NO20001171 L NO 20001171L
Authority
NO
Norway
Prior art keywords
naturally occurring
procedure
bone volume
increasing bone
selective agonists
Prior art date
Application number
NO20001171A
Other languages
English (en)
Other versions
NO20001171D0 (no
Inventor
James Richard Hartke
Mark Walden Lundy
Mitchell Anthony Delong
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO20001171D0 publication Critical patent/NO20001171D0/no
Publication of NO20001171L publication Critical patent/NO20001171L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er beskrevet nye metoder for å øke benvolum omfattende å administrere en ikke-naturlig forekommende FP-agonist til et individ som har behov for slik behandling. Det er videre beskrevet en fremgangsmåte ved behandling eller forebygging av bensykdommer omfattende å administrere en ikke-naturlig forekommende FP-agonist til et individ som har behov for slik behandling.
NO20001171A 1997-09-09 2000-03-07 FremgangsmÕte ved økning av benvolum under anvendelse av ikke naturlig forekommende FP-selektive agonister NO20001171L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5830697P 1997-09-09 1997-09-09
PCT/US1998/018338 WO1999012551A1 (en) 1997-09-09 1998-09-04 Method of increasing bone volume using non-naturally-occurring fp selective agonists

Publications (2)

Publication Number Publication Date
NO20001171D0 NO20001171D0 (no) 2000-03-07
NO20001171L true NO20001171L (no) 2000-05-09

Family

ID=22015996

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001171A NO20001171L (no) 1997-09-09 2000-03-07 FremgangsmÕte ved økning av benvolum under anvendelse av ikke naturlig forekommende FP-selektive agonister

Country Status (20)

Country Link
US (1) US6156799A (no)
EP (1) EP1045694A1 (no)
JP (1) JP2001515864A (no)
KR (1) KR20010023840A (no)
CN (1) CN1269721A (no)
AR (1) AR013479A1 (no)
AU (1) AU739275B2 (no)
BR (1) BR9811780A (no)
CA (1) CA2303800A1 (no)
CO (1) CO4980882A1 (no)
HU (1) HUP0004581A2 (no)
ID (1) ID24827A (no)
IL (1) IL134760A0 (no)
NO (1) NO20001171L (no)
PE (1) PE119099A1 (no)
PL (1) PL339288A1 (no)
SK (1) SK3412000A3 (no)
TR (1) TR200000662T2 (no)
WO (1) WO1999012551A1 (no)
ZA (1) ZA988228B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3385900A (en) * 1999-03-05 2000-09-21 Procter & Gamble Company, The Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
ATE283256T1 (de) * 1999-03-05 2004-12-15 Univ Duke C-16 ungesätigte fp-selektive prostaglandin analoge
IL145128A0 (en) * 1999-03-05 2002-06-30 Procter & Gamble Method of increasing bone volume using non-naturally-occurring ep1 selective agonists
CA2364948C (en) * 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
CA2303060A1 (en) * 1999-04-14 2000-10-14 United States Gear Corporation Towed vehicle brake controller
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US7545964B2 (en) 2000-08-29 2009-06-09 Imaging Therapeutics, Inc. Methods and devices for quantitative analysis of x-ray images
US6904123B2 (en) 2000-08-29 2005-06-07 Imaging Therapeutics, Inc. Methods and devices for quantitative analysis of x-ray images
US7467892B2 (en) 2000-08-29 2008-12-23 Imaging Therapeutics, Inc. Calibration devices and methods of use thereof
US7660453B2 (en) 2000-10-11 2010-02-09 Imaging Therapeutics, Inc. Methods and devices for analysis of x-ray images
US8639009B2 (en) 2000-10-11 2014-01-28 Imatx, Inc. Methods and devices for evaluating and treating a bone condition based on x-ray image analysis
DE60233485D1 (de) 2001-05-25 2009-10-08 Imaging Therapeutics Inc Verfahren zur diagnose, behandlung und prävention von knochenverlust
CN1893977B (zh) * 2001-07-23 2012-12-05 小野药品工业株式会社 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物
CN101921220B (zh) 2001-07-23 2013-05-22 小野药品工业株式会社 治疗与骨质损失有关的疾病的含有ep4激动剂作为活性成分的药物组合物
JP2006501138A (ja) * 2002-02-07 2006-01-12 ラットガーズ，ザ・ステート・ユニバーシティ・オブ・ニュージャージー ドラッグデリバリーのための治療用ポリ無水物化合物
US8600124B2 (en) 2004-09-16 2013-12-03 Imatx, Inc. System and method of predicting future fractures
US7840247B2 (en) 2002-09-16 2010-11-23 Imatx, Inc. Methods of predicting musculoskeletal disease
US8965075B2 (en) 2002-09-16 2015-02-24 Imatx, Inc. System and method for predicting future fractures
WO2004086972A2 (en) 2003-03-25 2004-10-14 Imaging Therapeutics, Inc. Methods for the compensation of imaging technique in the processing of radiographic images
US8290564B2 (en) 2003-09-19 2012-10-16 Imatx, Inc. Method for bone structure prognosis and simulated bone remodeling
US20080058613A1 (en) * 2003-09-19 2008-03-06 Imaging Therapeutics, Inc. Method and System for Providing Fracture/No Fracture Classification
EP1663002A4 (en) * 2003-09-19 2007-11-28 Imaging Therapeutics Inc METHOD FOR BONE STRUCTURE FORECAST AND SIMULATED BONE REFORMALIZATION
US8939917B2 (en) 2009-02-13 2015-01-27 Imatx, Inc. Methods and devices for quantitative analysis of bone and cartilage

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
WO1993015767A1 (en) * 1992-02-05 1993-08-19 Merck & Co., Inc. Implant therapy for bone growth stimulation
US5310759A (en) * 1992-08-12 1994-05-10 Bockman Richard S Methods of protecting and preserving connective and support tissues
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5747660A (en) * 1995-11-06 1998-05-05 The University Of Colorado Nucleic acid encoding prostaglandin F2α receptor regulatory protein
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists

Also Published As

Publication number Publication date
US6156799A (en) 2000-12-05
AR013479A1 (es) 2000-12-27
ZA988228B (en) 1999-03-09
HUP0004581A2 (hu) 2001-05-28
PE119099A1 (es) 2000-02-03
SK3412000A3 (en) 2000-12-11
CA2303800A1 (en) 1999-03-18
NO20001171D0 (no) 2000-03-07
ID24827A (id) 2000-08-24
BR9811780A (pt) 2000-09-12
TR200000662T2 (tr) 2000-07-21
JP2001515864A (ja) 2001-09-25
WO1999012551A1 (en) 1999-03-18
KR20010023840A (ko) 2001-03-26
PL339288A1 (en) 2000-12-04
CO4980882A1 (es) 2000-11-27
AU9219298A (en) 1999-03-29
AU739275B2 (en) 2001-10-11
EP1045694A1 (en) 2000-10-25
IL134760A0 (en) 2001-04-30
CN1269721A (zh) 2000-10-11

Similar Documents

Publication Publication Date Title
Hussein et al. Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model
Plonka et al. Zinc as an ambivalent but potent modulator of murine hair growth in vivo–preliminary observations
Raman et al. Pathway-specific variants of AMPA receptors and their contribution to neuronal signaling
NO944997L (no) Trombin-blodfraksjon for anvendelse ved en medisinsk fremgangsmåte
Stebbins et al. Prostaglandins contribute to cardiovascular reflexes evoked by static muscular contraction.
Falabella Repigmentation of leukoderma by minigrafts of normally pigmented, autologous skin
Ferland et al. Effects of methionine-enkephalin on prolactin release and catecholamine levels and turnover in the median eminence
Cruwys et al. The role of bradykinin B1 receptors in the maintenance of intra‐articular plasma extravasation in chronic antigen‐induced arthritis
Currie et al. Rod outer segments elongate in constant light: darkness is required for normal shedding
Tian et al. Rejuvenation of degenerative thymus by oral melatonin administration and the antagonistic action of melatonin against hydroxyl radical‐induced apoptosis of cultured thymocytes in mice
NO934137L (no) Fremgangsmaate for subkutan, suprafascial, pedikulaer, indre fiksering
Reddy et al. Deactivation of CFTR-Cl conductance by endogenous phosphatases in the native sweat duct
Colonna et al. Calcitonin gene-related peptide promotes cerebrovascular dilation during cortical spreading depression in rabbits
Corrodi et al. The Effect of Nerve Activity on the Depletion of the Adrenergic Transmitter by Inhibitors of Noradrenaline Synthesis 1
DK0840607T3 (da) Ny medicinsk anvendelse
FR2731907B1 (fr) Composition dermatologique et/ou cosmetique depigmentante et utilisation dans une methode cosmetique
NO984446L (no) FremgangsmÕte for behandling av smerte
Bendvold et al. The natural variations in prostaglandin concentration in human seminal fluid and its relation to sperm quality
Thomas et al. Effects of acute and chronic electroconvulsive shock on noradrenaline release in the rat hippocampus and frontal cortex
Korobko Review of current clinical studies of vitiligo treatments
T O'Shaughnessy et al. A1 adenosine receptor-mediated block of epileptiform activity induced in zero magnesium in rat neocortex in vitro
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
Hoang Van et al. The Efficacy of Non‐Cultured Epidermal Cell Suspension and Excimer Lamps Combination Therapy in Vitiligo: Results of 18 Months Follow‐Up
Chiarello Full‐face cryo‐(liquid nitrogen) peel
Fusi et al. Ca2+ entry blocking and contractility promoting actions of norbormide in single rat caudal artery myocytes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application